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doi:10.101The Triterpenoid CDDO-Me Delays Murine Acute
Graft-versus-Host Disease with the Preservation
of Graft-versus-Tumor Effects after Allogeneic Bone
Marrow Transplantation
Minghui Li,1 Kai Sun,2 Doug Redelman,3 Lisbeth A. Welniak,2 William J. Murphy2The occurrence of acute graft-versus-host disease (aGVHD) and tumor relapse represent the twomajor ob-
stacles impeding the efficacy of allogeneic bone marrow transplantation (BMT) in cancer.We have previously
shown that the synthetic triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid (CDDO) can inhibit
murine early aGVHD, but antitumor effects were not assessed. In the current study, we found that a new de-
rivative of CDDO, CDDO-Me, had an increased ability to inhibit allogeneic T cell responses and induce cell
death of alloreactiveT cells in vitro. Administration ofCDDO-Me tomice following allogeneic BMTresulted in
significant and increased protection from lethal aGVHD compared to CDDO. This correlated with reduced
TNF-a production, reduced donor T cell proliferation, and decreased adhesion molecule (a4b7 integrin)
expression on the donor T cells. CDDO-Me was also superior to CDDO in inhibiting leukemia growth in vi-
tro. When CDDO-Me was administered following an allogeneic BMT to leukemia-bearing mice, significant
increases in survival were observed. These findings suggest that CDDO-Me is superior to CDDO in delaying
aGVHD, while preserving or possibly even augmenting GVTeffects.
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Triterpenoid, CDDO-MeINTRODUCTION
Allogeneic bone marrow transplantation (BMT) is
currently used for the treatment of a variety of hemato-
logic malignancies. It has also shown promise in solid
cancers such as renal cell carcinoma [1,2] and in
autoimmunity [3,4], but significant obstacles regarding
acute graft-versus-host disease (aGVHD) still limit the
broader use of this procedure. GVHD is an immune-
mediated disease in which donor T cells are primed
mainly by recipient antigen-presenting cells and then
recognize and attack the genetically disparate recipient.
Proinflammatory cytokines produced by donor T cells1Department of Microbiology and Immunology, Univer-
Nevada School ofMedicine, Reno, Nevada; 2Department
rmatology, University of California at Davis, Sacramento,
rnia; and 3Department of Physiology and Cell Biology,
rsity of Nevada School of Medicine, Reno, Nevada.
isclosure: See Acknowledgments on page 749.
dence and reprint requests:William J.Murphy, PhD,De-
ent of Dermatology, University of California, Davis, Res 3
3300, 4645 2nd Avenue, Sacramento, CA 95817 (e-mail:
urphy@ucdavis.edu).
ugust 24, 2009; accepted January 26, 2010
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2010.01.020and other immune cells, have been shown to be critical
for GVHD generation and play an important role in
orchestrating the entire process [5,6]. In general,
efforts to reduce the incidence of GVHD have also
diminished beneficial graft-versus-tumor (GVT) re-
sponses with increased tumor relapse, suggesting that
these two processes are intimately linked [7].
Triterpenoids, biosynthesized in some plants by the
cyclization of squalene, have been used for medicinal
purposes in many Asian countries because of their
anti-inflammatory and anticarcinogenic properties
[8,9]. 2-Cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid
(CDDO) is a novel synthetic triterpenoid that is much
more potent than its parent compound. It has potent
differentiating, proapoptotic, and antiproliferative
capabilities on tumors, and anti-inflammatory proper-
ties as well [10,11]. CDDO is an agonist ligand for the
peroxisome proliferator-activated receptor g (PPARg);
however, its antitumor function can be PPARg-depen-
dent or independent [12,13]. Recently, we have shown
that CDDO can suppress allogeneic T cell response
and inhibit murine aGVHD, but the effects of CDDO
on GVT were not explored [14].
CDDO-Me, a synthetic C-28 methyl ester of
CDDO, has been shown to have even more potent
antitumor properties than CDDO [13,15-18], and739
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therapeutic agent for malignancies [18]. In the current
study, we compared the abilities of CDDO and
CDDO-Me to suppress murine aGVHD. We found
that administration of CDDO-Me was superior to
CDDO and significantly protected mice from
aGVHD in a fully major histocompatibility complex
(MHC)-mismatched murine BMT model. This was
associated with reduced donor T cell proliferation, de-
creased adhesion molecule (a4b7 integrin) expression
on the donor T cells, and reduced production of the
proinflammatory cytokine tumor necrosis factor
(TNF)-a. Importantly, GVT effects were preserved
when GVHD was delayed. These results suggest that
CDDO-Me may be of significant benefit in suppress-
ing aGVHD, while preserving or possibly even
augmenting GVT effects if it is applied together with
allogeneic BMT in cancer.MATERIALS AND METHODS
Animals
Female C57BL/6 (B6) and BALB/C mice were
obtained from the Animal Production Area of the
National Cancer Institute (Frederick, MD). The
mice were kept in specific pathogen-free conditions.
All animal protocols were approved by the Ethics
Committee for Animal Experimentation at the
University of Nevada, Reno. The mice were between
8 and 16 weeks of age at the start of the experiments.
Reagents and Media
CDDO-Me and CDDO were manufactured
through the NIH RAID Program and provided by
Reata Pharmaceuticals, Inc., Irving, TX. CDDO-Me
and CDDO were prepared in a vehicle solution of
10%DMSO (Sigma, St. Louis,MO), 10%Cremophor
EL (Sigma), and 80% 0.9% sodium chloride (Baxter,
Deerfield, IL). All mitogen assays and mixed lympho-
cyte reactions (MLRs)were cultured in completemedia
containing RPMI 1640 (Cambrex, Walkersville, MD),
supplemented with 10% fetal bovine serum (Gemini,
Woodland, CA), 10 mM HEPES, 2 mM L-glutamine
(Cambrex), 50 IU/mL penicillin/50 mg/mL streptomy-
cin (Mediatech, Herndon, VA), 1 mM nonessential
amino acids, 1 mM sodium pyruvate, and 50 mM
2-ME (Invitrogen, Grand Island, NY).
Mitogen Assay
Naı¨ve unfractionated BALB/C splenocytes (SCs)
were plated in quadruplicate in 96-well plates at a con-
centration of 2.5  105 cells per well, and were treated
with 2.5 mg/mL concanavalin A (ConA) (Sigma) in the
presence of various doses of CDDO-Me. Cells were
incubated for 24 hours at 37C and 5% CO2, and werethen pulsed with 1 mCi/well [3H] thymidine (MP Bio-
medicals, Solon, OH) for an additional 16 to 18 hours
prior to harvesting, and readon a 1450MicrobetaTrilux
scintillation counter (Wallac, Turku, Finland).
MLR
In the primary MLR, unfractionated BALB/C SCs
(2.5  105/well) and 30 Gy irradiated B6 SCs (2.5 
105/well) were plated in 96-well round-bottomed
plates in quadruplicate in complete media and incu-
bated at 37C with 5% CO2 for 3 days, then pulsed
with [3H]-thymidine (1 mCi /well) for 16 to 18 hours
prior to harvesting and counting.
In the secondary MLR assay, B6 SCs were T cell
depleted by incubating with anti-thy1.2 (30H12) and
rabbit complement, and then irradiated and incubated
with unfractionated BALB/C SCs in the presence of
CDDO-Me or vehicle control. After 3 days, cells were
harvested and washed twice, and then T cells were neg-
atively purified with a MACS system (Miltenyi Biotec,
Auburn,CA).Next, the same number of purified trypan
blue-exclusive T cells (0.8  105/well) from different
treatment groups were cultured with irradiated B6
SCs (2.5  105/well) for 3 days in the absence of
CDDO-Me and then pulsed with [3H] thymidine for
16 hours prior to harvesting and counting.
Carboxyfluorescein Succinimidyl Ester (CFSE)
Labeling and Cell Death Assessment
Unfractionated BALB/CSCswere labeled with 2.5
mMCFSE (Molecular Probes, Eugene, OR) as per the
manufacturer’s instructions. T cell-depleted SCs from
B6micewere prepared by incubatingwith anti-Thy 1.2
monoclonal antibody (mAb) (clone 30H-12), followed
by incubation with the rabbit complement. CFSE-
labeled BALB/C SCs (2.5  105 cells per well) were
cultured along with 2.5  105 irradiated (30 Gy) T
cell-depletedB6 SCs in the presence of various concen-
trations of CDDO-Me. On day 4 in the culture, cells
were harvested and labeled with PE-Cy5-conjugated
CD4 or CD8 antibodies and PE Annexin V (BD Phar-
mingen, San Diego, CA). During flow cytometry anal-
ysis, gates were drawn on CD4 or CD8-positive cells,
then on CFSEhigh/CFSElow cells, and the percentages
of Annexin V-positive cells were determined.
Flow Cytometry
Cells (1  106) were labeled with fluorochrome-
conjugated antimouse antibodies, and nonspecific
binding was corrected with isotype-matched controls.
FITC-anti-H2Dd (clone 34-2-12), PE-anti-LPAM-1
(clone DATK32), PE-anti-CD3 (clone 17A2), PE-
Cy5-anti-CD8a (clone 53-6.7), PE-Annexin V, and
7-AAD, were purchased from BD Biosciences. PE-
Cy5-anti-CD4 (GK1.5) was purchased from eBio-
science. All results were obtained on a BD FACScan
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Jose, CA). All data sets were analyzed using FlowJo
software (Tree Star, Ashland, OR).
Cell Cycle Assay
Cells (1 106) were fixed by cold 70% ethanol for at
least 1 hour at 4C, washed twice with cold phosphate-
buffered saline (PBS), and then incubated in PBS
containing 100 mg/mL RNase (Sigma) and 50 mg/mL
propidium iodide (PI) at 37C for 30 minutes. Data
were acquired on a Beckman Coulter EPICS XL-MCL
flow cytometer and analyzed with the FlowJo software.
Cytokine Analysis
The serum level of TNF-a on day 6 after BMTwas
determined by ELISA according to the manufacturer’s
instructions (R&D Systems, Minneapolis, MN).
Cell Preparation
Bonemarrow cell BMC suspensions were prepared
by gently releasing cells from the femurs, tibias, and
backbones into DPBS with a mortar and pestle. SCs
were prepared by gently crushing the spleens. The
cells were filtered to remove debris and washed twice
in DPBS for injection. Cell counts were performed
on a Coulter Z1 cell counter (Coulter Electronics,
Hialeah, FL).
BMT Studies
The B6 recipient mice received a myeloablative
dose (9 Gy) of total body irradiation (TBI) from
a 137Cs source, followed by the infusion of 10  106
BALB/C BMCs into the tail vein with or without
BALB/C SCs (20-40  106 cells) as a source of alloge-
neic T cells. Recipient B6 mice then received vehicle
control or CDDO-Me (200 mg/dose or 120 mg/dose,
once on day 0 and twice on day 1) intraperitoneally.
In the GVT studies, 6  105 C1498 myelogenous
leukemia cells (a gift from Dr. Bruce R Blazar of the
University of Minnesota, Twin Cities, MN) were in-
jected i.v. into the tail vein of B6 mice 11 days before
TBI. BMT was performed as described earlier. The
mice were monitored, and subjected to necropsy to
determine the cause of death.
Histologic Analysis
Representative samples of livers and colons were
obtained from transplant recipients on day 6 after
BMT and fixed in 10% neutral-buffered formalin.
Samples were then embedded in paraffin, cut into
5-mm-thick sections, and stained with hematoxylin
and eosin. All slides were coded and read in a blinded
fashion. The sections were visualized on a Nikon
Eclipse (E600) microscope and images were captured
on Coolpix camera and processed in Adobe Photoshop
for contrast and brightness.Statistics
Statistical analysis was performed using GraphPad
Prism 4 software (GraphPad, San Diego, CA). T cell
and tumor proliferation, and T cell death assays were
analyzed with the one-way analysis of variance
(ANOVA) and Dunnetts Multiple Comparison Test.
Survival data were plotted by the Kaplan-Meier
method and analyzed by the log-rank test. Adhesion
molecule data were analyzed with the unpaired
Student’s t test with the Welch correction. A P value
\ .05 in a 2-tailed analysis was considered significant.RESULTS
CDDO-Me Inhibits Alloantigen or Mitogen-
Induced T Cell Proliferation In Vitro
We first evaluated the effects of CDDO-Me on
murineT cell response to either alloantigen ormitogen
in vitro. The results showed that CDDO-Me can
significantly inhibit T cell responses to alloantigen in
the MLR (Figure 1A) (one-way ANOVA; P\ .001)
and themitogenConA (Figure 1B) (one-way ANOVA;
P\ .001) in a dose-dependent manner. In addition, it
was found that CDDO-Me resulted in a significantly
greater inhibition of allogeneic T cell responses when
concentration levels of 50 nM of CDDO and
CDDO-Me were compared (Figure 1A) (unpaired t
test; P\ .05). These results indicate that CDDO-Me
may be superior to CDDO in suppressing allogeneic
T cell responses in vivo.CDDO-Me Preferentially Induces Higher Cell
Death in Proliferating But Not Resting T Cells In
Vitro
Wenext assessed themechanism bywhichCDDO-
Me inhibited anMLR. CFSE dye dilution was used for
assessment of cell division and Annexin V binding was
used as amarker of cell death.The results demonstrated
that the addition of CDDO-Me to theMLR resulted in
significant increases of cell death in both alloreactive
CD41 and CD81 T cells (one-way ANOVA, P\ .05).
Of interest, dead cells were mainly in the CSFElow pop-
ulation (Figure 2A andB), which suggested that the pro-
liferating T cells were primarily targeted. This suggests
that CDDO-Me inhibits allogeneic T cell proliferation
in part via inducing the death of proliferating T cells.
To know whether surviving responder T cells in the
primaryMLR can still proliferate while being restimu-
lated with the same allogeneic stimulating cells, we pu-
rified the responder T cells and performed a secondary
MLR. The results demonstrated that the CDDO-
Me-treated surviving responder cells in the primary
MLR can still proliferate when restimulated with the
same allogeneic stimulating cells in the primary MLR
Figure 1. CDDO-Me inhibits alloantigen and mitogen-induced T cell proliferation. (A) BALB/C SCs were incubated with irradiated B6 SCs and then
pulsed with [3H] thymidine as described in Materials and Methods. T cell proliferation was significantly inhibited by CDDO-Me or CDDO (significant
differences compared with vehicle control and between 50 nM CDDO-Me and CDDO, *P\.001). (B) BALB/C SCs were exposed to ConA in the pres-
ence of CDDO-Me or vehicle and then pulsed with [3H] thymidine for 16 hours prior to harvesting as described in Materials and Methods. T cell pro-
liferation was significantly inhibited by CDDO-Me (*P\.001).
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CDDO-Me, the extent of proliferation was reduced.
CDDO-Me Administration Immediately after
BMT Delays GVHD Mortality in a Fully MHC-
Mismatched Model of Lethal aGVHD
After observing that CDDO-Me can significantly
inhibit allogeneic T cell response in vitro, we thenFigure 2. CDDO-Me preferentially induces cell death of proliferating, not res
SCs that were T cell depleted, in the different CDDO-Me concentrations. After
described in Materials and Methods. (A) Proportionally higher increases in Ann
(CFSEhigh) CD41 T cells in the presence of CDDO-Me (P\.05). (B) Proport
compared with nonalloreactive (CFSEhigh) CD81 T cells in the presence o
(P\.05). (C) Surviving responder T cells in the primary MLR can still prolife
The secondary MLR was performed as described in Materials and Methods. T
the primary MLR were restimulated with the same allogeneic stimulating cell
CDDO-Me groups, the extent of proliferation was reduced compared to theassessed the effects of CDDO-Me on murine
aGVHD. In these in vivo studies, lethally irradiated re-
cipient B6 (H2b) mice received BMCs with or without
30 to 40 million of SCs (as a source of allogeneic T
cells) from fully MHC-mismatched BALB/C (H2d)
donors. Then, vehicle control or CDDO-Me was ad-
ministered intraperitoneally to the recipients immedi-
ately after transplantation for 2 days. No morbidityting T cells. CFSE-labeled BALB/C SCs were incubated with irradiated B6
4 days in culture, cells were harvested and analyzed by flow cytometry as
exin V binding on proliferating (CFSElow) compared with nonalloreactive
ionally higher increases in Annexin V binding on proliferating (CFSElow)
f CDDO-Me. * Significant differences compared with vehicle control
rate while being restimulated with the same allogeneic stimulating cells.
here was significant proliferation when purified responder T cells from
s in the primary MLR (*P\ .05). However, at higher concentrations of
vehicle (P\.05).
Figure 3. CDDO-Me delays GVHD mortality in a fully MHC-
mismatched model of acute lethal GVHD to a greater degree than
CDDO. (A, B) Irradiated B6 mice received 10  106 BALB/c BMCs
with or without 40  106 BALB/C SCs as described in Materials and
Methods. Mice were treated with vehicle control or CDDO-Me (200
mg/dose, i.p. once on day 0 and twice on day 1). Significant increases in sur-
vival and decreases in weight loss were observed in CDDO-Me-treated
mice (,) compared with vehicle-treated mice (:) (P\.0001). (C) Irra-
diatedB6mice received10106BALB/CBMCswithorwithout 30 106
BALB/C SCs as described in Materials and Methods. Mice were treated
with the vehicle, CDDO, or CDDO-Me (120 mg/dose, i.p. once on day
0 and twice on day 1). Significant increases in survival were observed in
CDDO-Me-treated mice (,) compared with vehicle-treated mice (:)
and CDDO-treated mice () (P\.05). (D) Irradiated B6 mice received
10  106 BALB/C BMCs with or without 15 106 BALB/C SCs and
then were treated with vehicle control or 200 mg of CDDO-Me intraper-
itoneally on days 5 and 6. Accelerated GVHD-dependent mortality of
mice after allogeneic BMTwas observed when the mice were treated in
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BMCs alone and then treated with CDDO-Me or ve-
hicle control (Figure 3A). Among the mice that re-
ceived both allogeneic BMCs and SCs, the mice
treated with the vehicle control succumbed rapidly to
acute lethal GVHD. In marked contrast, the mice
treated with CDDO-Me exhibited delayed develop-
ment of lethal aGVHD and significant improvement
in survival (Figure 3A) (P \ .0001). In addition, al-
though both groups of the mice receiving BMCs and
SCs showed significant weight loss because of
aGVHD, the mice treated with CDDO-Me exhibited
less weight loss than the vehicle-treated mice
(Figure 3B) (P \ .05). The histology of mice also
showed that the administration of CDDO-Me allevi-
ated the damages to the liver and colon caused by early
GVHD (Figure 4). We next compared the effects of
CDDO-Me and CDDO on GVHD protection, and
found that CDDO-Me (120 mg/dose) significantly im-
proved the survival, but the same dose of CDDO (120
mg/dose) did not protect mice from aGVHD
(Figure 3C), suggesting that CDDO-Me is stronger
than CDDO in GVHD protection. These results
demonstrate that early administration of CDDO-Me
after allogeneic BMT is able to delay the development
of aGVHD and improve the survival of mice with
GVHD to a greater extent than CDDO.
In addition to the early administration of CDDO-
Me, we also explored the feasibility of later CDDO-
Me administration in GVHD protection. We have
previously demonstrated that the proteasome inhibi-
tor, bortezomib, could protect mice from GVHD
when administered early after BMT but markedly ac-
celerated GVHD-dependent mortality when adminis-
tration was delayed [19]. We found that delayed
administration of CDDO-Me (days 5 and 6), also ac-
celerated theGVHDmortality of mice after allogeneic
BMT, whereas the mice transplanted with BMCs.
alone tolerated the delayed administration of
CDDO-Me (Figure 3D). When CDDO-Me was ad-
ministered early (days 0 and 1) to suppress GVHD
and then continued with the delayed administration
(days 5 and 6), the acceleration in GVHD mortalitydelay on days 5 and 6 (,) compared with vehicle-treated mice (:)
(log-rank test, P\.05). (E) Irradiated B6 mice received 10  106 BALB/
C BMCs with or without 40  106 BALB/C SCs and were treated with
vehicle control or 200 mg of CDDO-Me intraperitoneally on different
days. Early plus delayed administration of CDDO-Me (days 0, 1, 5, and
6;) accelerated the mortality of GVHDmice compared with only early
administration (,) (log-rank test, P\.05). Compared to only early ad-
ministration (,), early plus late administration of CDDO-Me (days 0,
1, 13, and 14;C) neither accelerated themortality ofGVHDnor supplied
better protection from GVHD (P. .05). Representative data from 1 of 3
independent experiments are presented for A and B. Representative data
from 1 of 2 independent experiments are presented for C-E. Each exper-
iment consisted of 7 mice per treatment group in GVHD induction arms
and 3-4 mice in BMT control arms.
Figure 4. CDDO- Me alleviates liver and colon damage caused by early aGVHD. Irradiated B6 mice were transplanted with 10  106 BALB/C BMCs
with or without 40 106 SCs and then treated with CDDO-Me (200 mg/dose) or vehicle control as described in Materials and Methods. Each treatment
group consisted of 4 mice. Histology of liver (A-D) and colon (E-H) from representative recipients on day 6 after BMTare shown (magnitude 400). In
vehicle or CDDO-Me-treated mice transplanted with only BMCs (A-B and E-F), liver, and colon showed normal appearance. In vehicle-treated GVHD
mice (C and G), liver revealed portal area inflammation with mononuclear cell infiltration; colon showed extensive inflammation in the lamina propria,
goblet cell depletion, and crypt cell destruction. In CDDO-Me–treated GVHD mice (D and H), liver had reduced portal area inflammation, and colon
showed attenuated inflammation and goblet cell depletion compared with vehicle-treated mice.
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augmentation of GVHD associated with delayed
CDDO-Me administration overcame the protection
seen with early administration. Interestingly, in the
GVHD mice treated with late administration of
CDDO-Me on days 13 and 14 following early admin-
istration, no accelerated GVHD mortality was ob-
served (Figure 3E). All these results indicate that
administration of CDDO-Me can delay aGVHD
when administered immediately after BMT, but can
also promote GVHD-dependent mortality when
administration is delayed, and the paradoxic effects
of CDDO-Me on GVHD are critically dependent on
the timing of CDDO-Me administration.Figure 5. CDDO-Me decreases proinflammatory cytokine TNF-a and reduce
were transplantedwith 10 106 BALB/C BMCs and 30-40 106 SCs, and then
Materials and Methods. Each treatment group consisted of 4 to 5 mice. (A) Sig
CDDO-Me-treated mice on day 6 post-BMT. (B) Significant reduction in dono
on day 5 of post-BMT (Student’s t test; P\.05). Representative data from 1 oCDDO-Me Decreases Serum TNF-a Production
and Reduces Donor-Derived T Cell Expansion
after Allogeneic BMT
Proinflammatory cytokines play a central role in
the pathogenesis of aGVHD [5]. TheTNF-a blockade
in vivo significantly alleviated murine GVHD and
showed activity to steroid-refractory human GVHD
[20,21]. Therefore, we examined whether CDDO-
Me affected TNF-a production in mice undergoing
GVHD. The results showed that serum TNF-a levels
on day 6 after allogeneic BMT were significantly
decreased in the mice treated with CDDO-Me
(Figure 5A) (P\ .05). Thus, decreased TNF-a was as-
sociated with reduced GVHD in the mice treated withs donor-derived T cell expansion after allogeneic BMT. Irradiated B6mice
treated with CDDO-Me (200 mg/dose) or vehicle control as described in
nificant decreases (Student’s t test; P\.05) in TNF-a were observed in
r-derived CD31 splenocytes were observed in CDDO-Me-treated mice
f 3 independent experiments are presented.
Figure 6. CDDO-Me reduces LPAM-1 (a4b7 Integrin) expression on donor T cells. Irradiated B6 mice received 10 106 BALB/C BMCs and 30 106
SCs, andwere treated with CDDO-Me (200 mg/dose) or vehicle control as described in Materials andMethods. Each treatment group consisted of 4 to 5
mice. (A-D) Significant decreases in LPAM-1-positive donor T cell frequency were observed in the mesenteric lymph nodes and spleens of CDDO-Me-
treated mice on day 5 post-BMT (Student’s t test; P\.05). Representative data from 1 of 3 independent experiments are presented.
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T cells, we also examined the effects of CDDO-Me
treatment on donor T cell expansion in recipients.
The results showed that CDDO-Me administration
significantly reduced the total number of donor T cells
in the spleens of recipient mice on day 5 after alloge-
neic BMT (Figure 5B) (P\ .05). This finding corre-
lated with the delay of GVHD in the treated mice.
CDDO-Me Reduces the Expression of a4b7
Integrin on Donor T Cells
The a4b7 integrin is a critical adhesion molecule
that mediates T cells homing to the intestine, a primary
target in aGVHD [22]. Therefore, we examined the
effects of CDDO-Me treatment of recipient mice on
the expression of this adhesion molecule on donor T
cells after transfer. The results showed that CDDO-
Me administration reduced a4b7 integrin-positive do-
nor T cell percentage in the mesenteric lymph nodes
(MLNs) and spleen on day 5 after allogeneic BMT
(Figure 6) (P \ .05). These results suggest that
CDDO-Memay suppress aGVHD in part via reducing
donor T cell homing to the host intestine in addition to
decreasing donor T cell proliferation in recipient mice.
GVTActivity Is Preserved by CDDO-Me
Administration after Allogeneic BMT in
Advanced Tumor-Bearing Mice
CDDO-Me has been shown to have more potent
antitumor properties than CDDO in a variety of tumor
cells [13,15-18]. In the present study, we compared the
ability ofCDDOandCDDO-Me to inhibit the prolifer-
ation of C1498 cell line (a murine acute myelogenous
leukemia cell line). The results showed that CDDO-
Mewas significantlymorepotent thanCDDOon the in-
hibitionofC1498 cell proliferation (Figure 7A) (P\.05)
making this a more attractive agent to use in the treat-
ment of leukemia. We next assessed the mechanisms
bywhichCDDO-Me inhibitedC1498 cell proliferation.
Low concentration of CDDO-Me inhibited C1498 cell
proliferation by causing cell cycle arrest in theG1phase,
whereas high concentrations of CDDO-Me worked by
causing cell cycle arrest in theG2/Mphase and inducing
apoptosis (Figure 7B-D).
CDDO-Me was able to inhibit tumor cell prolifer-
ation directly and suppress GVHD by immunosup-
pression; however, it may also adversely affect the
beneficial GVT effects associated with allogeneic
BMT by suppressing the donor T cells. Therefore,
we evaluated whether GVT activity was preserved by
CDDO-Me administration after allogeneic BMT in
advanced tumor-bearing mice. To explore whether
GVT effects were preserved after CDDO-Me admin-
istration, we injected mice intravenously with C1498
cells 11 days before allogeneic BMT. When the mice
were treated with CDDO-Me alone after receivingthe tumor, no protective effects of CDDO-Me alone
were observed with the dose and regimen of CDDO-
Me we used in these advanced tumor-bearing recipi-
ents (Figure 8A). Modest increases in survival were
observed when mice received allogeneic BMT alone
(Figure 8A) (P \ .05) and the addition of CDDO-
Me in recipients receiving BMT alone did not lead
to significant increases in survival (Figure 8A). When
the tumor-bearing mice received allogeneic BMT
with donor splenocytes, all vehicle-treated mice
rapidly succumbed to aGVHD (Figure 8B). Only the
tumor-bearing mice that received allogeneic BMT
with donor splenocytes and CDDO-Me showed sig-
nificant increases in survival (Figure 8B) (P \ .05).
The majority of these mice eventually died of aGVHD
rather than tumor burden based on necropsy, indicat-
ing that significant GVT effects had been preserved.
These results indicate that CDDO-Me can delay
GVHD and preserve GVT effects after allogeneic
BMT in advanced tumor-bearing mice.DISCUSSION
Triterpenoids are a large family of structures
synthesized in some plants such as the chrysanthemum
flower through the cyclization of squalene, and have
been used in traditional Asian medicine for centuries
[23]. Naturally occurring triterpenoids like oleanolic
acid (OA) and ursolic acid (UA) have weak anti-
inflammatory and anticarcinogenic activities [8,9].
To increase their usefulness, a series of novel
derivatives of OA and UA have been synthesized, and
some derivatives of OA are much more potent than
the parent compound in suppressing nitric oxide
production from interferon (IFN)-gamma-stimulated
macrophages [24]. CDDO is one of these synthetic de-
rivatives that has potent differentiating, proapoptotic,
and antiproliferative capabilities on tumors, and
anti-inflammatory properties [10,11]. CDDO-Me is
a synthetic C-28 methyl ester of CDDO and has
been shown to have more potent antitumor properties
than CDDO [13,15-18]. Also, CDDO-Me is more
potent than CDDO in the activation of Keap1-Nrf2-
ARE pathway, which is involved in cytoprotection un-
der excessive electrophile or oxidative stress [25,26].
CDDO is an agonist ligand for PPARg; in contrast,
CDDO-Me has been found to be an antagonist for
PPARg in 3T3-L1 cells [27]. In addition, CDDO sig-
nificantly upregulates DR4/DR5 expression on PPC-1
cells (prostate cancer cells), but CDDO-Me does
not affect their expression on these cells although
CDDO-Me has been shown to upregulate DR4/DR5
expression on H1792 cells (human lung cancer cells)
[18,28]. These findings suggest that the effects of
CDDO-Me on DR4/DR5 expression are cell type de-
pendent. The knockdown of DR4/DR5 by RNAi
Figure 7. CDDO-Me inhibits C1498 proliferation by causing cell cycle arrest and/or apoptosis to a greater degree than CDDO in vitro. C1498 cells (3
 105/well in a 24-well plate) were cultured in the presence of different concentrations of CDDO-Me or CDDO for 24 hours. (A) Cell numbers were
counted by a Coulter Z1 cell counter. Significant inhibition of C1498 tumor cell proliferation was observed in the presence of CDDO-Me (P\.001). The
inhibition was also observed in the presence of a higher concentration of CDDO (P\.01). (B, C) Cell cycle assay was performed as described in Ma-
terials and Methods. Compared with the vehicle, the low concentration of CDDO-Me (200 nM) caused cell cycle arrest in G1 phase (*P\.05), and high
concentrations of CDDO-Me ($400 nM) caused cell cycle arrest in G2/M phase and more cells in sub-G1 (*P\.05). (D) Apoptosis assay was performed
by flow cytometry with PE-Annexin V and 7-AAD. Apoptosis was observed when C1498 cells were incubated in high concentrations of CDDO-Me.
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Figure 8. Treatment with CDDO-Me preserves GVL activity and im-
proves leukemia-free survival. (A, B) B6 mice received 6  105 C1498
cells, and then 120 mg/dose CDDO-Me or vehicle control twice on
days 11 to 12 and once on days 24 to 25 after tumor injection (N 5 7-
9/group). (A) No difference in survival was observed in nontransplanted
mice. Some mice were irradiated (9 Gy) on day 11 after tumor cell injec-
tion, followed by injection of 10 106 BALB/C BMCs on day 11. Alloge-
neic BMT provided significant protection in tumor survival compared
with nontransplant treatment (P\ .05); however, CDDO-Me did not
improve survival of tumor-bearing mice subjected to allogeneic BMT
compared with vehicle control (P . .05). Results from the combination
of 2 independent experiments are presented. (B) Some groups addition-
ally received 25million BALB/C SCs on day 11.Mice that received vehicle
control injections succumbed to GVHD-associatedmorbidity (:). Mice
that received CDDO-Me (,) survived significantly longer than either
CDDO-Me-treated tumor-bearing mice (-; P \ .05) or mice that
received aBMTwithout SCs andCDDO-Me treatment (6; P\.05). Rep-
resentative data from 1 of 2 independent experiments are presented.
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by CDDO, in contrast, DR4/DR5 RNAi does not
affect the apoptosis induced by CDDO-Me [18].
These data suggest that the apoptosis of PPC-1 cells
induced by CDDO, but not CDDO-Me, is dependent
on DR4/DR5 death receptor expression. We have
found that CDDO-Me can upregulate IFN-gamma
receptor-a expression, whereas CDDO downregu-
lated its expression on C1498 cells (unpublished
data), suggesting different mechanisms of action are
occurring. All these suggest that although CDDO-
Me is a derivative of CDDO, it is different from
CDDO in some aspects in addition to the fact that it
is more potent than CDDO on antitumor activities
and cytoprotection under stress. In the previous study,
we found that CDDO suppressed allogeneic T cell re-
sponse and alleviated murine aGVHD [14]. In the cur-
rent study, we found that CDDO-Me administeredimmediately after BMT delayed murine aGVHD,
which was associated with reduced donor T cell prolif-
eration, decreased TNF-a level, and reduced gut hom-
ing receptor (a4b7 Integrin) expression on the donor
T cells. In addition, we found that CDDO-Me was
more potent than CDDO on GVHD protection.
The dissociation of GVHD and GVT remains to be
a great challenge in improving the efficacy of alloge-
neic BMT. The data presented here demonstrate
that CDDO-Me can markedly delay lethal aGVHD
while retaining GVT responses in advanced tumor-
bearing mice. These results suggest that CDDO-Me
may be of significant value for removal of the minimal
residual tumor disease that can exist after BMT.
Of interest, we found that early administration of
CDDO-Me immediately after allogeneic BMT
delayed aGVHD; however, delayed administration of
CDDO-Me (days 5 and 6) resulted in marked accelera-
tion of GVHD mortality and even overcame the
protection seen with early administration. However,
the later administration of CDDO-Me (days 13 and
14) did not accelerate GVHD mortality. CDDO-Me
has recently been demonstrated to block the NF-kB
pathway by inhibiting Inhibitory kappa B alpha (IkBa)
kinase (IKK) [29,30]. NF-kB is critical for immune
responses, especially cytokine responses, and has an
antiapoptotic function by upregulating the synthesis
of many antiapoptotic gene products [31]. So, it is pos-
sible that delayed administrationofCDDO-Memay re-
sult in sensitization of the target organs in GVHD to
donor immune cells and/or inflammatory cytokine-
mediated injury. This phenomenon, although to
a much stronger degree, has been reported to occur
with the proteasome inhibitor, bortezomib [19,32,33],
suggesting similar mechanisms exist. Significant
increases in gastrointestinal lesions have been found
following delayed bortezomib administration during
GVHD, which correlated with significant increases of
type 1TNF-a receptor transcription in gastrointestinal
cells and with significant increases of TNF-a, IL-1b,
and IL-6 levels in the serum [19]. Decreased toxicity
in delayed bortezomib administration can be achieved
by removal of CD41T cells from the graft or by inhib-
iting TNF-a [32].
The priming of naive T cells by antigens in
secondary lymphoid organs leads to the generation
of effector T cells exhibiting a capacity to enter periph-
eral extralymphoid tissues. Effector T cells generated
in different lymphoid organs display distinct tissue
homing tropism, for example, the T cells activated in
Peyer’s patches andmesenteric lymph nodes highly ex-
press a4b7 Integrin and CCR9 exhibiting gut homing
tropism [22]. The a4b7 integrin (LPAM-1, lympho-
cyte Peyer patch adhesion molecule) is responsible
for T cell specificly homing into Peyer’s Patches
and intestinal lamina propria via its binding to
MAdCAM-1 (mucosal addressin cell adhesion
Biol Blood Marrow Transplant 16:739-750, 2010 749CDDO-Me delays Acute GVHD and Preserves GVTmolecule), that is present on high endothelial venules
(HEVs) in Peyer’s Patches and flat-walled venules in
lamina propria [34]. A humanized mAb to a4b7 integ-
rin, MLN02, has shown efficacy in the treatment of in-
flammatory bowel disease [35]. It has also been found
that allogeneic a4b7
2/2 donor T cells cause less
GVHD morbidity and mortality than a4b7
1/1 donor
T cells, which is associated with reduced homing of
donor T cells to host intestinal mucosa [36]. A recent
study using b7 knockout T cells in aGVHDmodel fur-
ther supports the role of a4b7 integrin in T cell homing
to gut and intestinal GVHD induction. Recipients of
b7 knockout donor T cells in a murine GVHD model
demonstrated less GVHD morbidity and mortality
than recipients of wild-type T cells, associated with
a decrease in donor T cell infiltration of the intestine
[37]. The results presented here demonstrate that
CDDO-Me treatment after allogeneic BMT is associ-
ated with a reduction in a4b7 integrin-positive donor T
cells in the MLNs and spleen. These findings suggest
that CDDO-Me may delay aGVHD in part by reduc-
ing donor T cells homing to host intestine in addition
to reducing donor T cell proliferation.
In summary, the data presented here demonstrate
that CDDO-Memay be of significant use in alleviating
aGVHDwhile preserving or possibly even augmenting
GVT effects if it is applied together with allogeneic
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